Cargando…
A Novel Combination Treatment with Honokiol and Rapamycin Effectively Restricts c-Met-Induced Growth of Renal Cancer Cells, and also Inhibits the Expression of Tumor Cell PD-L1 Involved in Immune Escape
The mTOR inhibitor Rapamycin has tumor inhibitory properties; and it is also used as an immunosuppressive agent after organ transplantation. However, prolonged Rapamycin treatment re-activates Akt and can promote cancer growth. Honokiol is a natural compound with both anti-tumorigenic and anti-infla...
Autores principales: | Sabarwal, Akash, Chakraborty, Samik, Mahanta, Simran, Banerjee, Selina, Balan, Murugabaskar, Pal, Soumitro |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7408055/ https://www.ncbi.nlm.nih.gov/pubmed/32635337 http://dx.doi.org/10.3390/cancers12071782 |
Ejemplares similares
-
Novel Honokiol-eluting PLGA-based scaffold effectively restricts the growth of renal cancer cells
por: Hamedani, Yasaman, et al.
Publicado: (2020) -
A novel combination therapy with Cabozantinib and Honokiol effectively inhibits c-Met-Nrf2-induced renal tumor growth through increased oxidative stress
por: Rawat, Laxminarayan, et al.
Publicado: (2023) -
Honokiol inhibits c-Met-HO-1 tumor-promoting pathway and its cross-talk with calcineurin inhibitor-mediated renal cancer growth
por: Balan, Murugabaskar, et al.
Publicado: (2017) -
Activation of c-Met in cancer cells mediates growth-promoting signals against oxidative stress through Nrf2-HO-1
por: Chakraborty, Samik, et al.
Publicado: (2019) -
Honokiol inhibits the growth of SKBR3 cells
por: Shi, He, et al.
Publicado: (2020)